Despite many eorts to alter the relentlessly aggressive progression of tumors of neural origin, individuals bearing these tumors exhibit poor prognosis for longterm survival. In an attempt to ®nd an eective treatment, we examined the ecacy of the non-steroidal anti-in¯ammatory drug,¯urbiprofen, to suppress the growth of tumor cell lines derived from medulloblastoma and glioblastoma multiforme. Results from cell proliferation assays have revealed that¯urbiprofen eectively inhibits the growth of various tumor cells in a dosedependent manner and causes a noticeable change in the progression of cells through cell cycle stages. Treatment of tumor cells with¯urbiprofen reduced the number of cells in G1 and G2, and signi®cantly increased their numbers in S phase, suggesting that,¯urbiprofen accelerates G1/S entry, and/or delays cell exit from S to G2/M stages. Results from RNase protection assay and Western blot analysis showed that while treatment of cells with¯urbiprofen causes a minor change in the RNA level of dierent cyclins, there is a signi®cant decrease in the level of cyclin B protein upon¯urbiprofen treatment. Examination of tumor suppressors by RNase protection technique showed a subtle increase in the levels of several tumor suppressors upon¯urbiprofen treatment. Interestingly, at the protein level, p53 tumor suppressor was substantially increased upon¯urbiprofen treatment, yet the level of p21, a downstream target for p53 remained unchanged. Curiously, treatment of the cells with urbiprofen enhanced the level of COX-2 expression. Results from co-immunoprecipitation showed association of COX-2 with p53 in tumor cells. These observations suggest that the interaction of COX-2 with p53 may cause p21-independent suppression of tumor cell growth upon¯urbiprofen treatment. Oncogene (2001) 20, 6864 ± 6870.
Introduction
Non-steroidal anti-in¯ammatory drugs (NSAIDs) have been widely used for treatment of minor injuries and headaches, degenerative joint diseases such as rheumatoid arthritis, and prophylaxis against cardiovascular disease (DuBois et al., 1998) . Recent studies have provided evidence for an additional role for NSAIDs in preventing growth of cancer cells by inhibiting cyclooxygenase (COX) enzymes (Grubbs et al., 2000; Wechter et al., 2000a,b; Williams et al., 2000) . The two isoforms of COX enzyme, COX-1 and COX-2, catalyze the reaction of arachadonic acid to various forms of prostaglandins (DuBois et al., 1998; Smith and Marnett, 1991; Williams and DuBois, 1996) . COX-1 is expressed ubiquitously and seems to have a cytoprotective role, especially in the gastrointestinal lining, whereas COX-2 expression is part of an in¯ammatory response. Further, COX-2 has been detected in a variety of tumors including adenomatous polyposis, colorectal cancer, squamous carcinomas, pancreatic cancer, gastric adenocarcinoma, and esophogeal adenocarcinoma (Souza et al., 2000; Zhang et al., 1999) . Examination of COX-1 and COX-2 expression in a collection of 50 glioma samples revealed the detection of COX-1 in macrophage/ microglial cells within the tumor parenchyma of 20 ± 50% of samples and COX-2 expression was observed in tumor cells (Deininger et al., 1999) . Other studies revealed upregulation of COX-2 in a variety of high grade glioma and inhibition of COX-2 by NS-398 in human astrocytic cell lines (Joki et al., 2000) .
Recently, we focused our eort on understanding the pathways involved in the genesis of brain tumors, in particular medulloblastoma and glioblastoma multiforme in an attempt to develop therapeutic strategies toward the treatment of these tumors. Medulloblastomas are primitive neuroectodermal tumors (PNETs) (Fung and Trojanowski, 1995; Hart and Earle, 1973; Molenaar and Trojanowski, 1994) , which are predominantly found in the cerebellum and infrequently seen in other brain regions including the cerebrum, spinal cord, and pineal gland. Medulloblastomas account for 6 ± 8% of all brain tumors and nearly 20% of malignant tumors aecting the central nervous system (CNS) of adolescents (Molenaar and Trojanowski, 1994) . This type of brain tumor is very aggressive and frequently appears in children before the age of 2 years. The average time from onset of symptoms to diagnosis is 3 months, with death occurring an average of 10 months from the onset of symptoms (Hart and Earle, 1973) .
Glioblastomas are the most aggressive and frequent brain tumor, accounting for 12 ± 15% of all brain tumors. These tumors, which develop mainly in older adults between the ages of 45 ± 70 years, are highly malignant and less than 2% of glioblastoma patients survive past 3 years (Kleihues and Cavanee, 2000) . While the molecular events involved in the development of medulloblastoma and glioblastoma are not fully understood, it is believed that, deregulation of the cell cycle pathway eventually leads to uncontrolled proliferation of cells and the development of tumors in brain. Control of cell cycle is accomplished through the interplay of a series of regulatory events involving pairs of cyclins and cyclin dependent kinases, tumor suppressor proteins, and transcription factors that orchestrate coordinate expression of genes involved in S phase transition (Kohn et al., 1994) . Mutations and/ or deregulated expression of cyclins and tumor suppressors results in cells which are unable to regulate progression through the cell cycle, rapidly proliferate in vitro and in vivo, and possess phenotypes seen in cancer cells. The use of molecular approaches and/or pharmaceuticals to inhibit cell proliferation by increasing the level of tumor suppressor gene expression and reducing the level of activity and expression of cyclins/ cdks, provide a plausible avenue for treatment of tumor cells.
Here we describe our recent observations supporting the antiproliferative eects of the NSAID¯urbiprofen on cells from human medulloblastoma and glioblastoma multiforme. We have shown the ability of urbiprofen to suppress the growth of the tumor cells in a dose dependent manner. This eect is marked by a reduction in DNA synthesis, an accumulation of cells in S phase which is concomitant with a severe decrease in the cell numbers found in G2 phase of the cell cycle. The cell cycle arrest observed by¯urbiprofen is accompanied by a signi®cant decrease in cyclin B levels whose activity is important in G2 phase, and a substantial increase in the level of p53 tumor suppressor protein, whose function is important in cell cycle checkpoints. These observations suggest that urbiprofen exerts its anti-proliferative eect in brain tumor cells by modulating expression of cyclins and/or tumor suppressor proteins. Further, our ®ndings on the interaction of COX-2 with p53 in¯urbiprofen treated cells oer a new role for COX-2 in the control of cell proliferation via a p53 pathway.
Results and discussion
Three independent methods including MTT, cell counting, and BrdU incorporation assays were used to examine the eect of¯urbiprofen on the growth of human medulloblastoma cells, Daoy. Results from MTT assay revealed that while the amount of metabolically active cells in the untreated control cells progressively increased during the 96 h, treatment with urbiprofen inhibited cellular proliferation ( Figure 1a ). The dierence in metabolic activities between the treated and untreated cells appeared between 24 ± 48 h following treatment and became more noticeable at 72 ± 96 h following treatment. Although a basic MTT activity was detected in the treated cells at 96 h, its level was signi®cantly lower than that seen in continuously proliferating untreated cells.
Examination of the total number of cells at 0, 24, 48, 72 and 96 h after treatment with either 1, 0.1, 0.2, 0.4 mM of¯urbiprofen showed a dose dependent decrease in the cell number (Figure 1b) . The inhibition The eect of¯urbiprofen on cell proliferation was also detected in two other tumor cell lines, T98G, a human glioblastoma cell line and TE671 another human medulloblastoma cell line. As shown in Figure  1c and d, in both cell lines¯urbiprofen inhibited cell proliferation in a dose dependent manner.
In the next experiment, Daoy cells were pulse labeled with BrdU for 4 h and incorporation of BrdU was detected with a¯uorescently labeled antiBrdU antibody followed by counterstaining with propidium iodide (PI), which labels the nuclei of all cells in culture. . This is an interesting observation suggesting that¯urbiprofen may exert its action on cell proliferation by retarding cell cycle progression which may eventually, after several days, lead to apoptosis.
Analysis of cell cycle progression of untreated and urbiprofen treated cells revealed no apparent dierence in the cell cycle distribution after 24 and 48 h of treatment (Table 1) . After 72 h, the population of cells in G2/M phase began to decrease in¯urbiprofen treated cells versus untreated cells (17.3 versus 28.3%). After 96 h of treatment, signi®cant dierences were observed in both the G2/M and S phases of the treated versus untreated cells. While 19.9% of the untreated cells were detected in G2/M, only 5.1% of the treated cells were found in this phase of the cell cycle. Conversely, the number of cells in S phase was signi®cantly increased from 27.6% in untreated cells to 49.7% in¯urbiprofen treated cells. Further, a modest decrease in cell proliferation in the G1 stage was noticed upon treatment with¯urbiprofen and no pre-G1 peak representing apoptotic population was observed. This observation shows a major deregulation of the cell cycle at the G2/M phase which results in cell accumulation in S phase and a decrease in G2/M phase.
In the next series of experiments, we examined the level of cell cycle regulators at the RNA level by RNase protection assay (RPA) and at the protein level by Western blot analysis.
First, we examined the levels of cyclin gene expression. Results from RPA showed no drastic dierences in the level of various cyclin RNAs ( Figure  3a) . Examination of several cyclins including cyclin A, B and D by Western blot analysis showed no drastic dierences in the levels of cyclin A and D at the protein level upon treatment of cells with¯urbiprofen (data not shown). However, the level of cyclin B, whose primary function is at the G2/M phase, was signi®cantly decreased in cells treated with¯urbiprofen (Figure 3b ). These observations suggest that whilē urbiprofen has no signi®cant eect on the level of cyclin gene expression at the RNA level, it drastically decreases the level of cyclin B protein, presumably by increasing the rate of its turnover. Under similar conditions, the levels of cyclin A, D1, and E, and cdc2, cdk2, and cdk4 remained unchanged (data not shown). Figure 3b also illustrates that the level of control Grb-2 protein showed no variation upon treatment. We also utilized a similar technique to determine the level of tumor suppressor gene expression at the RNA and protein levels. Results from RPA showed a minor, if any, increase in the intensity of the bands corresponding to RNAs from several tumor suppressors such as p53, p27, p21, and p18 (Figure 4a) . Interestingly, results from Western blot experiments showed that p53 is substantially increased at the protein level after treatment of cells with¯urbiprofen (Figure 4b) . No signi®cant dierences in the level of the p21 tumor suppressor and the Grb-2 protein were observed (Figure 4b ). These observations indicated that treatment of cells with¯urbiprofen increases the level of p53 after 24 h and that this level remains unchanged for 48 h.
In the next experiment, we examined the level of cyclooxygenase-2 (COX-2) in untreated and¯urbipro-fen treated Daoy cells. As shown in Figure 5a , treatment of these cells with¯urbiprofen signi®cantly enhanced the levels of COX-2 expression after 24 and 48 h. Again, the level of several control proteins including Grb-2 remained unchanged (data not shown). The observed increases in the level of COX-2 protein and p53 upon¯urbiprofen treatment provided a rationale to examine the interaction between these two proteins. Total protein extracts from the untreated and¯urbiprofen-treated Daoy cells after 24 h were mixed with two dierent anti-p53 antibody and the immunocomplex was analysed for the presence of COX-2 by Western blot using anti-COX-2 antibody. As illustrated in Figure 5b , a band corresponding to COX-2 was detected in the immunocomplex pulled down by anti-p53 antibody. Again, the level of Grb-2 protein in this experiment was determined in parallel and showed no signi®cant dierences (data not shown).
The chemopreventative eects of several NSAIDs have been studied by several groups and the results have provided evidence supporting their therapeutic potential in various malignancies. For example, sulindac is used for the treatment of familial adenomatous polyposis (FAP) (Matsuhashi et al., 1997) . This drug causes a regression in the number and size of polyps in humans and induces the level of expression of the tumor suppressor protein, p21, in colon cancer cells (Goldberg et (Wechter et al., 2000a,b) . Recent studies have shown the ecacy of celecoxib and sulindac sulfone on the inhibition of colorectal cancer (Taylor et al., 2000; Williams et al., 2000) . Here, we provide evidence for the ability of¯urbiprofen to suppress growth of tumors of CNS origin including medulloblastoma and glioblastoma multiforme. Results from the biochemical studies reveal that while¯urbiprofen treatment decreases the level of cyclin B, there is a signi®cant increase in the level of the tumor suppressor protein, p53. These observations corroborate results from cell cycle studies indicating de-regulation at the S and G2 phases of the cell cycle, where cyclin B plays an important regulatory role. Further, an increase in the number of cells at S phase with no evidence for active DNA synthesis, as shown by BrdU incorporation, suggests that the cell cycle checkpoints, which are partly under the control of p53, are tightly regulated in the treated cells and that upregulation of this protein may dictate the slow progression of cells from G1 to S and S to G2/M. However, accumulation of p53 in S phase arrested cells can occur without function (Gottifredi et al., 1999) . Comparison of our results from RNA and protein studies suggest that the observed increase in the level of p53 and decrease in cyclin B expression may primarily occur at the post-transcriptional level, perhaps due to changes in the stability of the protein. As the increase in the stability of p53 can be achieved by its association with other proteins, we investigated the possible inter-relation of p53 with several cellular proteins including COX. Our results show the association of p53 with COX-2 in¯urbiprofen treated tumor cells. While the relevance of this observation in the anti-in¯ammatory activity of¯urbiprofen remains unknown, one may speculate the stabilization of p53 upon its association with COX-2 may involve an underlying mechanism for anti-tumor activity of urbiprofen. Gottifredi et al. (1999) demonstrated that blocking DNA synthesis can result in p53 accumulation without function. This could account for the stable level of p21 in both untreated and treated cells. It is also possible that¯urbiprofen may mediate COX-2/p53 interaction. In light of earlier data demonstrating that R¯urbiprofen has the ability to inhibit the activity of several important inducible transcription factors including NF-kB and AP1 (Tegeder et al., 2001; von Knethen et al., 1999) , it is also possible that functional interaction of p53 and NF-kB subunits, which has been shown to control cell cycle events, serves as an alternative pathway to enable¯urbiprofen in suppressing cell proliferation.
Results from in vitro studies provide the rationale to initiating in vivo animal studies to examine the ecacy of¯urbiprofen as a treatment for brain tumors.
Materials and methods

Cell lines
Human medulloblastomas (Daoy and TE671) and human glioblastoma multiforme (T98G) were cultured in DMEM supplemented with 10% fetal bovine serum (GibcoBRL 1 , Rockville, MD, USA). All cell lines grow as a monolayer and were maintained at 378C in 7% CO 2 .
Cell proliferation assay
A colormetric MTT assay was performed (Cell Proliferation Kit I (MTT)), as recommended by the manufacturer's protocol (Roche Molecular Biochemicals, Indianapolis, IN, USA). In brief, cells were plated in 96-well¯at bottom titer plate at a density of 1610 3 cells/well. The cells were treated in triplicate with either 0.1, 0.2, 0.4 mM of¯urbiprofen ([+]-2-¯uoro-a-methyl-4-biphenylacetic acid, Sigma, St. Louis, MO, USA) every 24 h for 96 h at concentrations derived from Warner et al. (1999) . MTT labeling reagent was added at 0, 24, 48, 72 and 96 h, and the cells were solubilized for 4 h overnight at 378C. The colormetric evaluation was performed by a microtiter plate reader (DYNEX Technologies, Chantilly, VA, USA) at 570 nm and the data quantitated.
A bromodeoxy uridine (BrdU) incorporation assay was performed using the 5-Bromo-2'-deoxy-uridine Labeling and Detection Kit I according to the manufacturer's protocol (Roche Molecular Biochemicals, Indianapolis, IN, USA). Brie¯y, cells were treated with either ethanol or 100 mg/ml of urbiprofen every 24 ± 96 h. Subsequently, cells were treated for 4 h with BrdU, washed, ®xed and stained with an antibody to BrdU conjugated to¯uorescein to determine the amount of incorporated BrdU into newly synthesized DNA.
Cell proliferation was assessed by counting the cell number. Cells were plated in 35 mm petri dishes at a density of 1610 4 cells/plate and treated with either ethanol vehicle control, 0.1, 0.2, 0.4 mM of¯urbiprofen daily. Cells were collected at 0, 24, 48, 72 and 96 h after the treatment and the total cell number was determined under phase contrast microscopy using a brightline hemocytometer.
Western blot
Cell lysates were prepared in ice-cold lysis buer containing 50 mM Tris (pH 7.5); 150 mM NaC1; 0.5% IPEGAL CA-630 v/v (Sigma, St. Louis, MO, USA). One hundred microgram protein samples were analysed on a 4 ± 15% SDS ± PAGE (BioRad, Hercules, CA, USA) and after transfer to membrane transblots were incubated in TBS-T buer containing 10 mM Tris (pH 8.0); 150 mM NaC1; 0.1% Tween 20 v/v; 5% milk for 16 h at 48C and then reacted with mouse anti-p53 antibody (clone G59-12, Pharmingen, San Diego, CA, USA), and mouse anti-cyclin B1 antibody (clone Ab-2, Calbiochem, San Diego, CA, USA) at a 1 : 1000 dilution in buer containing 1% milk in TSG-T. After 90 min incubation at room temperature, a secondary antibody conjugated to horseradish peroxidase (HRP) was added at a dilution of 1 : 10 000 in 5% milk in TBS-T and incubated rocking at room temperature for 30 min. Protein-antibody complexes were detected using ECL TM Western blotting detection reagents as speci®ed by the manufacturer (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Speci®c bands were visualized by exposing the blot to X-ray ®lm.
Immunoprecipitation
Protein lysates (200 mg) from 24 h untreated and¯urbiprofen treated Daoy cells were incubated rotating overnight at 48C with either anti-p53 antibody, Ab-1 or anti-p53 antibody, Ab-2 (Calbiochem, San Diego, CA, USA). Protein complexes were pulled down by incubating while rotating at 48C with 25 ml of pre-washed Pansorbin (Calbiochem) for 2 h. The Pansorbin/protein complex was then washed twice in lysis buer and ®nally resuspended in 30 ml of 26 SDS loading buer, then incubated for 45 min at room temperature. Samples were spun down and supernatant was removed and diluted with an equal part of lysis buer and run on a 4 ± 15% SDS ± PAGE gel as described above. After transferring, the blot was probed using anti-COX-2 antibody (C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
RNase protection assay
mRNA levels for cyclins and tumor suppressors were assessed using the Riboquant TM multi-probe RNase protection assay system (Pharmingen, San Diego, CA, USA). The assay was performed according to the instructions provided by the supplier using 10 mg of RNA. Gels were exposed to autoradiography ®lm and then a phosphor screen (Molecular Dynamics, Sunnyvale, CA, USA). The phosphor screen was scanned using a Molecular Imager 1 FX (BioRad, Hercules, CA, USA) to determine relative band intensities.
Flow cytometry
The cells were pulse labeled with 10 mM BrdU for 45 min prior to¯urbiprofen treatment. Cells were collected at appropriate time points, washed twice with PBS, and after ®xation in 100% ethanol at 48C, cells were collected by centrifugation and were resuspended in 0.5 ml of PBS containing 10 mg/ml of propidium iodide and 250 mg/ml of RNase A. Samples were incubated at 378C for 30 min and kept at 48C until¯ow cytometry was performed with Becton Dickinson FACscan¯ow cytometer.
